Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18606 | 1.00 | GCKR (1.00) | GCKRGCK | |
| SCHEMBL18311 | 1.00 | GCKR (1.00) | GCKRGCK | |
| SCHEMBL12078673 | 1.00 | GCKR (1.00) | GCKRGCK | |
| SCHEMBL16526 | 1.00 | GCKR (1.00) | GCKRGCK | |
| SCHEMBL12078496 | 1.00 | GCKR (1.00) | GCKRGCK | |
| SCHEMBL15832 | 1.00 | GCKR (1.00) | GCKRGCK | |
| SCHEMBL18505 | 0.92 | GCKR (1.00) | GCKRGCK | |
| SCHEMBL16452 | 0.92 | GCKR (1.00) | GCKRGCK | |
| SCHEMBL16609 | 0.92 | GCKR (1.00) | GCKRGCK | |
| SCHEMBL16529 | 0.92 | GCKR (0.86) | GCKRGCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609081-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | Amgen Inc. (US) | 2013-07-03 | — | — | EP | claimed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | claimed |
| EP-2609081-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | Amgen Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |